ANIMALCARE GROUP PLC
("Animalcare" or the "Company")
Exercise of Options and Total Voting Rights
15 May 2024. Animalcare Group plc (AIM: ANCR), the international animal health business, announces that, following an exercise of options awarded at nil cost under the Company's Long Term Incentive Plan over 44,485 new ordinary shares of 20p each in the Company ("New Ordinary Shares"), application has been made to the London Stock Exchange for the admission of 44,485 New Ordinary Shares to trading on AIM. It is expected that admission of the New Ordinary Shares will become effective and dealings will commence at 08:00am on 21 May 2024.
The New Ordinary Shares, when issued, will be fully paid and will rank pari-passu in all respects with the existing ordinary shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. The issue and allotment of the New Ordinary Shares will be within the Company's existing authorities.
Total Voting Rights
Subsequent to admission, there will be 60,152,411 ordinary shares of 20p each in issue with voting rights. No shares are held in treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Enquiries:
| Animalcare Group plc | |
| Chris Brewster, Chief Financial Officer and Company Secretary | +44 (0)1904 487 687 communications@animalcaregroup.com
|
| Stifel Nicolaus Europe Limited (Nominated Adviser & Joint Broker) | +44 (0)20 7710 7600 |
| Ben Maddison Nicholas Harland Francis North
| |
| Panmure Gordon (Joint Broker) | +44 (0)20 7886 2500 |
| Corporate Finance Freddy Crossley/Emma Earl Corporate Broking Rupert Dearden
| |
About Animalcare www.animalcaregroup.com
Animalcare Group plc is a UK AIM-listed international development-focused veterinary sales and marketing organisation. Animalcare operates in seven countries and exports to approximately 40 countries in Europe and worldwide. The Group is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
